In February 2020, the U.S. Food and Drug Administration requested the withdrawal of the weight-loss drug, Belviq and Belviq XR (lorcaserin). The administration took this move because a safety clinical trial showed that Belviq could increase the occurrence of cancer. Manufacturer Eisai Inc. voluntari
On March 2, 2020, online pharmacy Valisure announced in a press release that it had detected N-nitrosodimethylamine (NDMA)–a probable human carcinogen—in samples of prescription drug products containing metformin, a common type 2 diabetes treatment. Considering these results, the company filed a Cit
After the U.S. Judicial Panel on Multidistrict Litigation (JPML) ordered the consolidation of all federally filed Zantac lawsuits into the Southern District of Florida, District Judge Robin L. Rosenberg scheduled the first status conference for March 20, 2020. At that time, the lawyers involved will
A Florida woman recently filed a Zantac lawsuit against current and past producers of the acid-reducing medication. She claims that after using the product, she suffered from serious injuries, and she seeks to hold the defendants liable. The case was filed in the U.S. District…
In October 2019, Johnson & Johnson (J&J) issued a voluntary recall of a single lot of its Baby Powder. The Food and Drug Administration (FDA), when testing one sample of that Baby Powder, had discovered sub-trace levels of asbestos, so J&J implemented the recall out…
The Food and Drug Administration (FDA) recently announced a recall of three lots of Mylan nizatidine capsules because tests indicated the presence of trace amounts of N-nitrosodimethylamine (NDMA). NDMA has been classified as a probable human carcinogen and is the same chemical that has recently…
In September 2019, the U.S. Food and Drug Administration (FDA) warned healthcare providers and patients that ranitidine drugs, including brand-name Zantac, had been found to contain N-nitrosodimethylamine (NDMA), a probable human carcinogen. The warning sent ripples through the healthcare community,
On December 18, 2019, the Food and Drug Administration (FDA) announced yet another generic ranitidine recall, this time implemented by Glenmark Pharmaceutical Inc. The company is pulling all prescription ranitidine tablets (150 mg and 300 mg) from the U.S. market because they may contain unacceptab
Nine plaintiffs have jointly filed a new Zantac cancer lawsuit in the U.S. District Court for the District of New Jersey. The plaintiffs have named as defendants all Zantac manufacturers, including Boehringer Ingelheim Pharmaceuticals, Chattem Inc., GlaxoSmithKline, Pfizer, and the current manufact
Two plaintiffs—one from New York and the other from Virginia—recently filed a new generic Zantac (ranitidine) class-action lawsuit in the U.S. District Court for the Southern District of New York. The plaintiffs claim that generic ranitidine manufacturer Perrigo Company put consumers at risk when s
Following a wave of Zantac and generic ranitidine recalls, a Colorado man has filed a new Zantac lawsuit against the manufacturers of the heartburn medication. The plaintiff alleges that he used Zantac for about 23 years, and as a result, developed bladder cancer. He filed…
While Zantac (ranitidine) manufacturer Sanofi maintains that its product is safe, Australian drug regulators recently announced that three-quarters of the ranitidine samples they tested contained high levels of N-nitrosodimethylamine (NDMA), a probable human carcinogen. Sanofi recently recalled Zant
